The Syk Inhibitor Fostamatinib Decreases the Severity of Colonic Mucosal Damage in a Rodent Model of Colitis (original) (raw)

Favorable response to subcutaneous administration of infliximab in rats with experimental colitis

John Triantafillidis

World Journal of Gastroenterology, 2005

View PDFchevron_right

Biologic Therapies for Inflammatory Bowel Diseases

Vassilis Valatas

2013

View PDFchevron_right

Defensins and cytokines in inflammatory bowel disease

Arman Rahman

2007

View PDFchevron_right

Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease

Maikel Peppelenbosch

Gastroenterology, 2002

View PDFchevron_right

Bugs, genes, fatty acids, and serotonin: Unraveling inflammatory bowel disease?

Jonathan Kaunitz

F1000Research, 2015

View PDFchevron_right

The impact of JNK inhibitor D-JNKI-1 in a murine model of chronic colitis induced by dextran sulfate sodium

Waldemar Uhl

Journal of Inflammation Research, 2013

View PDFchevron_right

Pathology of Inflammatory Bowel Disease

Shiva Raj K.C.

Journal of Pathology of Nepal, 2015

View PDFchevron_right

99th Dahlem Conference on Infection, Inflammation and Chronic Inflammatory Disorders: Host–microbe interactions in the gut: target for drug therapy, opportunity for drug discovery

Fergus Shanahan

Clinical and Experimental Immunology, 2010

View PDFchevron_right

Features of Microscopic Colitis in Cancer Patients Receiving Immune Checkpoint Inhibitors

Rashmi Samdani

American Journal of Gastroenterology, 2018

View PDFchevron_right

Role of the JNK signal transduction pathway in inflammatory bowel disease

Jack Bragg

World Journal of Gastroenterology, 2008

View PDFchevron_right

Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence

Pablo Olivera

Digestive and Liver Disease, 2018

View PDFchevron_right

Indian Society of Gastroenterology consensus on ulcerative colitis

GANESH RAMESH

Indian Journal of Gastroenterology, 2012

View PDFchevron_right

Anti-inflammatory effect of acute stress on experimental colitis is mediated by cholecystokinin-B receptors

Mehmet Gülpınar

Life Sciences, 2004

View PDFchevron_right

P-005: Mechanism of action of potential live biotherapeutics for the treatment of inflammatory bowel disease

George Grant

Journal of Crohn's and Colitis, 2014

View PDFchevron_right

When to use biological agents in inflammatory bowel disease

Rupert Leong

Journal of Gastroenterology and Hepatology, 2012

View PDFchevron_right

Therapeutic effects of IkB kinase inhibitor during systemic inflammation

Vera Geraldes

International Immunopharmacology, 2020

View PDFchevron_right

The efficacy of tyrosine kinase inhibitor dasatinib on colonic mucosal damage in murine model of colitis

selim demirtaş

Clinics and Research in Hepatology and Gastroenterology, 2016

View PDFchevron_right

American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome

Lucinda Harris

The American Journal of Gastroenterology, 2018

View PDFchevron_right

The role of diet in the management of irritable bowel syndrome: a focus on FODMAPs

Ali Mohtashim

Expert Review of Gastroenterology & Hepatology, 2018

View PDFchevron_right

Biologics, Small Molecules and More in Inflammatory Bowel Disease: The Present and the Future

Saurabh dawra

Future pharmacology, 2024

View PDFchevron_right

Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis

Stephen Middleton

Gastroenterology, 2014

View PDFchevron_right

Immunogenicity of biologics used in the treatment of inflammatory bowel disease: A review

Angray Kang

Human antibodies, 2021

View PDFchevron_right

Treating Irritable Bowel Syndrome: A Fresh and Minty Approach to an Old Therapy

Lucinda Harris

Digestive Diseases and Sciences, 2015

View PDFchevron_right

FNDC4 acts as an anti-inflammatory factor on macrophages and improves colitis in mice

Sven Almer

Nature Communications, 2016

View PDFchevron_right

Fibrotic Strictures and Anti-TNF-α Therapy in Crohn’s Disease

Giovanni Terrosu

Digestion, 2007

View PDFchevron_right

Abnormal Motility in Patients With Ulcerative Colitis

Fabio Potenti

Archives of Surgery, 2002

View PDFchevron_right

Efficacy of IL12/23 Blockade Expands Our Therapeutic Targets and Challenges the Old Dogma in Ulcerative Colitis

Gerassimos Mantzaris

Gastroenterology, 2020

View PDFchevron_right

Management of acute, severe ulcerative colitis

David Sachar

Journal of Digestive Diseases, 2012

View PDFchevron_right

Evaluation of inflammatory activity in Crohn’s disease and ulcerative colitis

Maria de Lourdes Abreu Ferrari

World Journal of Gastroenterology, 2012

View PDFchevron_right

Sishen Pill Treatment of DSS-Induced Colitis via Regulating Interaction With Inflammatory Dendritic Cells and Gut Microbiota

Bishwajeet Prakash

Frontiers in Physiology

View PDFchevron_right

Pharmacogénétique de l’infliximab dans la maladie de Crohn

Vinciane Dideberg

Acta Endoscopica, 2007

View PDFchevron_right

Irritable bowel syndrome–like symptoms are re-lated to gut inflammation in clinical remission phase of inflammatory bowel disease

Hamid Tavakkoli

Journal of Research in Medical Sciences, 2012

View PDFchevron_right

Inflammatory Bowel Disease Sometimes Lead to Life-threatening Complications

Siniša Franjić

View PDFchevron_right

The Src kinase Fyn is protective in acute chemical-induced colitis and promotes recovery from disease

Patrick Schenck, Arthur Wang

Journal of leukocyte biology, 2015

View PDFchevron_right

Induction and Maintenance Therapy With Infliximab for Children With Moderate to Severe Ulcerative Colitis

Robert Baldassano

Clinical Gastroenterology and Hepatology, 2012

View PDFchevron_right